>
State of Play is a read on a sector: its size, its structure, where the money moves and what moves it. Each edition takes one market and sets out what is known, what is claimed, and what the difference between the two is worth to anyone deciding where to commit.
A market built on public rails as good as any, gated by the arithmetic of acquisition, and missing the one thing that would fix it: a payer. A premium briefing on India’s digital-health market, the public rails it runs on, the unit economics that gate it, and the payer it is still missing.
Figures carry their basis and their date. Where published estimates disagree, the range is given and the basis named rather than averaged away, and where a widely quoted number does not survive checking it is corrected here rather than repeated. Every chart plots a figure stated in the text, and nothing is projected beyond what a named source projects.
India built some of the best digital-health plumbing on earth. Then it discovered that almost nobody could make money running water through it.
The paradox of Indian digital health is that the rails are public and the economics are not. India has built, at the scale of a billion people, some of the finest public digital-health infrastructure anywhere: 90 crore digital health IDs, 100 crore linked records, and a free state teleconsultation service that has handled 43 crore consultations. The rails are extraordinary. They are also public. And they sit on top of an absence. The market that runs on them has no payer.
The result is a sector with a brilliant supply side and a broken demand side. Every private digital-health platform still spends more to win a customer than that customer is worth: on the cleanest available proxy, India’s leaders burn ₹1.12 to ₹1.21 to earn a single rupee of revenue. The cause is structural, not managerial. India’s public insurance scheme, PM-JAY, pays for the hospital but explicitly excludes outpatient care, which is precisely what telemedicine and e-pharmacy sell. Three things follow.
Both sides of the argument have moved since this page was written. The argument holds. On the rails, the Ayushman Bharat Digital Mission had
issued about 93.95 crore ABHA health accounts and linked some 105 crore health records by July 2026 (National Health Authority, 2026). eSanjeevani recorded 50,00,92,730 cumulative teleconsultations on 15 September 2026 (MoHFW, 2026). The free public alternative is therefore roughly a sixth larger than the figure carried above, and the supply side of the paradox has strengthened rather than stabilised.
The opportunity is real and the rails are as good as any, but the value goes to whoever cracks the unit economics, by stacking or by reaching the payer, and not to anyone who simply rides the rails.
On the payer side, the first genuine movement in years is now visible. Health insurance accounted for 40.8 per cent of India’s non-life gross premium in FY26, against 38.6 per cent in FY25, overtaking motor to become the largest line. Segment premium rose 15.4 per cent to about ₹1.4 lakh crore, against industry growth of 9.3 per cent (IRDAI and CareEdge
Ratings, 2026). The proximate cause is fiscal. The 56th GST Council removed the 18 per cent levy on individual life and health premiums with effect from 22 September 2025, although group health remains taxed at that rate (Ministry of Finance, 2025).
The exclusion at the centre of the argument is unchanged. Ayushman Bharat PM-JAY had issued 48.5 crore cards by 21 September 2026 across more than 38,000 empanelled hospitals (National Health Authority, 2026), and it still pays for hospitalisation rather than for the clinic. Out-of-pocket spending remains above 60 per cent of health expenditure on the reconciled basis used in the Volge playbook (2026). The payer is closer than it was. It has not arrived.
India fixed the infrastructure problem of digital health long before it fixed the business problem.
India’s public infrastructure runs years ahead of its private economics. The state has laid rails the rich world would envy: a national health identity carried by 90 crore people, a billion linked records, a free teleconsultation service reaching every state and union territory. And yet the companies built to run on those rails are, almost to a one, loss-making, freshly out of a brutal funding correction.
The distance between the rails and the returns is not a technology gap. The apps work. The rails work, and the demand is enormous. It is an economics gap. The cost of acquiring and serving a paying customer outruns the value that customer generates, because the core product, an outpatient consultation or a medicine order, is low-value and infrequent. The decisive point is that it is paid for by no one but the patient. India built the railway before it found the freight that pays.
The distance has widened on the measurable side. The public identity layer has passed 93.95 crore health accounts and about 105 crore linked records (National Health Authority, July 2026). The free national teleconsultation service crossed 50 crore cumulative consultations on 15 September 2026 (MoHFW, 2026). The physical network behind that service is larger than the consultation count alone conveys. More than 142,000 Ayushman Arogya Mandirs now operate as spokes, against 19,473 hubs and 901 online out-patient departments, and they are served by roughly 242,000 registered doctors, specialists and health workers (MoHFW, October 2026).
Correct the nomenclature wherever it appears. The facilities described in earlier editions as Health and Wellness Centres became Ayushman Arogya Mandirs in 2023, and it is the Mandirs that carry the public teleconsultation channel into rural India. The name matters because the spoke, not the app, is the point of access for the citizen who owns no device, and the state owns the spoke.
Against that public landscape stands a private base that is broad and shallow. Trackers count roughly 11,000 health-technology firms in India, of which an estimated 90 per cent remain pre-revenue or below ₹1 crore of annual revenue. The top five firms hold about 60 per cent of revenue in teleconsultation and e-pharmacy. Between 20 and 30 per cent of the base
is expected to fail or be absorbed within two years (Tracxn and industry trackers, 2026). The infrastructure is national. The industry on it is a handful of platforms and a long tail.
Ask how big Indian digital health is and you get an answer somewhere between $6 billion and $16 billion. Both are defensible. That is the problem.
The single most slippery number in this sector is its own size. Estimates for the 2024–25 market run from about $6.3 billion to $16.1
billion, a two-and-a-half-fold spread. The cause is almost entirely definitional. Statista’s narrow, consumer-app count lands near $6 billion. Grand View and IMARC, folding in enterprise software and electronic records, reach $14–16 billion. The growth rates diverge just as wildly, from about 12% to nearly 40% a year, and should never be averaged together.
The numbers you can trust are the segments. Telemedicine is put at roughly $5.5 billion by 2025 and is the largest slice at about 45% of revenue; e-pharmacy at roughly $3.7 billion. The move, for an operator or investor, is to distrust the headline and read the parts. The market is real and growing fast. Its “size”, however, is a definitional artefact. The question that matters is not how big it is but which pieces of it can be made to pay.
The spread measures scope rather than disagreement about India. The remedy is to commit to one basis and state it. On the reconciled basis used internally, the market is put at roughly $15 billion to $18 billion for 2025, with $17.81 billion on the broadest construction (Custom Market Insights, 2025). Narrower telehealth definitions land near $3.9 billion for the same year, projected to about $9.8 billion by 2030 at some 20 per cent a year (Mordor Intelligence, 2025). The long projection, above $100 billion by 2033 at a compound rate of 20 to 25 per cent, is direction of travel rather than forecast.
Two features of the market matter more than its headline. The base is broad and shallow: of approximately 11,000 health-technology firms, an estimated 90 per cent are pre-revenue or below ₹1 crore of revenue
(Tracxn, 2026). And growth is no longer evenly distributed, since capital and revenue are concentrating in a small number of platforms that own several segments at once.
The practical consequence for an operator or an investor is that segment boundaries are becoming commercial rather than strict. A share figure quoted for teleconsultation or for e-pharmacy describes a revenue line inside a platform more often than it describes a company. The useful question is not how large the market is but which of its parts can be made to pay.
The number that decides this market is not its size. It is the cost of a single customer.
The wall every Indian digital-health company runs into is unit economics. What it costs to win and serve a customer is set against what that customer is worth. No platform discloses raw acquisition cost and lifetime value. The cleanest proxy is therefore also the bluntest: how many rupees a company spends to earn one. In FY25, Tata 1mg spent about ₹1.12 to earn ₹1; MediBuddy, about ₹1.21. Spending more than you make is the sector’s baseline condition. It is not the exception.
The cause is built into the product. A teleconsultation can carry a healthy gross margin of around 70%. But it is low-value and infrequent, and it barely upsells, so the cost of acquiring the user rarely repays in a single transaction. E-pharmacy runs on thin margins against capital-heavy logistics, knife-fight pricing and near-zero switching costs. The demand is vast and the product works, but the economics of a one-off, low-ticket health purchase simply do not clear the cost of winning the person who makes it. Everything else here responds to this one ceiling. The stacking, the consolidation and the hunt for a payer follow from it.
Spend-to-earn ratios from audited FY25 filings (Entrackr). Margins: Redseer. No platform discloses raw CAC/LTV; ratios are the best proxy.
The ceiling can be stated more directly than through a spend-to-earn ratio, and the direct statement is harsher. Acquiring a teleconsultation user costs ₹800 to ₹2,000 or more, against a single consultation worth ₹300 to ₹800. No first transaction repays the cost of the customer who makes it
(Volge playbook, 2026). Worked through, a venture acquiring at ₹1,200 and selling a ₹500 consultation at a 50 per cent gross margin earns a contribution of ₹250. That recovers a fifth of its acquisition cost. Roughly fourteen to twenty-four further consultations are required to reach a lifetime value of three to five times that cost.
The segment margins on which that arithmetic rests are lower than is often quoted. On the internal basis, teleconsultation gross margins run 40 to 60 per cent and e-pharmacy 15 to 25 per cent, below the figures carried in the panel above. The ceiling is therefore if anything higher than the ratios imply. The accepted benchmarks are a lifetime value of at least three to five times acquisition cost, a payback period under twelve months and a repeat rate of 40 to 60 per cent. The majority of the sector clears none of them.
The denominator can be changed where the numerator cannot. A user acquired through a corporate contract at about ₹300, generating recurring annual revenue, repays within months, and business-to-business acquisition costs of ₹150 to ₹500 per user are routine. The route out of the ceiling is therefore a change of channel and bundle rather than a change of price.
The deepest reason digital health cannot pay for itself in India is brutally simple: no one pays for what it sells.
In most health systems a third party pays for the care a patient receives, a government scheme or an insurer, and that is what makes the provider’s economics work. In India, for the outpatient care digital health overwhelmingly delivers, that third party is missing. Out-of-pocket spending still runs near 39% of health expenditure by the national accounts, and
around half by international measures. That is among the highest on earth. The patient pays, in cash, for the consultation and the medicine.
The state scheme does not close the gap, because of one decisive exclusion. Ayushman Bharat (PM-JAY) offers a ₹5 lakh family cover, has issued more than 36 crore cards, and now runs in every state, but it covers only inpatient, secondary and tertiary hospitalisation. Outpatient care is explicitly carved out. So India’s largest health payer does not pay for the thing digital health sells. Private health insurance is growing, health is now the biggest non-life line, but individual cover is barely a tenth of it. The acquisition cost the ceiling describes is, in the end, uncovered. There is no one to absorb it.
Two of the figures on this page need re-basing, and the correction sharpens the argument. PM-JAY had issued 48.5 crore cards by 21 September 2026 across more than 38,000 empanelled hospitals (National Health Authority, 2026), a scheme far larger than the count given above and still confined to inpatient, secondary and tertiary care. Out-of-pocket spending is better stated at above 60 per cent of health expenditure on the reconciled internal basis (2026) than at the lower national-accounts
figure, which places India among the most cash-funded health systems of its income group.
The payer pool that could close the gap is nonetheless growing faster than the industry around it. Health insurance reached 40.8 per cent of non-life gross premium in FY26, from 38.6 per cent in FY25, overtaking motor. Segment premium grew 15.4 per cent to about ₹1.4 lakh crore and retail health 19.9 per cent, against industry growth of 9.3 per cent (IRDAI and CareEdge Ratings, 2026). The proximate cause is fiscal. It is the removal of the 18 per cent GST on individual life and health premiums from 22 September 2025, group health remaining taxed (56th GST Council, 2025). The market is estimated near $16 billion in 2025 and about $48.5 billion by 2035 (Mordor Intelligence and IMARC, 2025).
Early movement is visible on the public side as well. PM-JAY has begun reimbursing teleconsultation in selected states, and the scheme has been extended to citizens aged 70 and above. The white spaces that would relieve the ceiling are specific: out-patient cover, mental-health cover, senior inclusion and rural penetration.
The cheap capital that once hid the unit economics has gone home. Its absence put the problem under a spotlight.
For a few giddy years, abundant venture capital let Indian digital-health firms spend straight through the unit-economics ceiling, buying growth at a loss on the faith that scale would eventually fix the maths. That era is over. Funding into Indian healthtech fell from a 2021 peak near $1 billion to a 2023 trough of about $419 million. It rebounded to roughly $1.13 billion in 2024, then settled to around $700 million in 2025, a reset year in which deal counts fell and the sector slid down the venture rankings. The first half of 2026 brought about $310 million, and it went to AI, oncology and genomics rather than the old consumer plays.
The discipline that reset imposed is the most consequential thing to happen to the sector. With growth-at-all-costs money gone, companies had to face the ceiling head-on, cutting marketing, narrowing focus, chasing
the path to profitability the next part lays out. A much-quoted “$9.9 billion” is cumulative all-time funding, not a single year, and should not be read as a flood; the real picture is a sector recovering on tighter terms. The capital winter did not kill Indian digital health. It made it grow up.
The composition of the reset is more instructive than its level. The 2024 rebound was spread across 112 deals, and the first quarter of 2025 alone drew about $496 million across 38 rounds (Tracxn and industry trackers, 2026). By the first half of 2026 the concentration had tightened sharply. Only four rounds above $100 million were recorded nationally, against eleven a year earlier. The money went to artificial intelligence and oncology, and to genomics, rehabilitation and precision medicine. Roughly 30 per cent of health-technology venture capital now flows to medtech and diagnostics rather than to pure teleconsultation.
The repricing of the 2021 cohort is the defining feature of the cycle. It was executed at the level of individual companies rather than through a
general markdown. PharmEasy’s parent took ₹1,804 crore in 2024 at a steep discount to its peak, led by a domestic family office. Pristyn Care was valued at about $1.17 billion in November 2025, down some 17 per cent from its $1.4 billion peak (Entrackr and Inc42, 2026). Undifferentiated direct-to-consumer brands have seen early-stage funding contract hardest.
Appetite for the sector itself has not gone. More than 39 new health-technology ventures were founded in the first half of 2025. The capital requirement at each stage is modest by medtech standards, at ₹1 crore to ₹5 crore at seed and ₹50 crore to ₹150 crore at Series B. What has changed is the test applied. A calculated acquisition cost, lifetime value and payback period are now screened before growth is funded.
India’s digital-health rails are a genuine world first, population-scale public infrastructure, built in five years.
The Ayushman Bharat Digital Mission (ABDM) applies India’s “India Stack” playbook, the one that produced Aadhaar and UPI, to health. The scale is recent and staggering. The ABHA digital health ID, carried by 14.7 crore people in 2021, passed 90 crore by 2026; the records linked to those IDs crossed 100 crore in May 2026, doubling in roughly fifteen months. A registry of more than 363,000 facilities and over 564,000 practitioners completes the directory.
The whole thing is consent-first by design. ABDM’s Health Data Management policy moves data only on explicit, purpose-bound, time-limited, withdrawable consent, brokered through a Consent Manager. That body is the health twin of the Account Aggregator. Discovery and booking run on the Unified Health Interface, built on the Beckn protocol, the same open standard behind ONDC in commerce. Open, interoperable, consent-based and built for a billion people, the rails are as good as any in the world. The question is not whether they exist, but whether anyone can build a paying business on top of them.
The counts given here have been overtaken and should be re-based. The ABHA health account passed 90 crore on 30 May 2026 and stood at
about 93.95 crore by July 2026, against 84.79 crore in January 2026. Linked health records crossed the 100-crore mark over the same period to reach some 105 crore, from 82.69 crore in January (National Health Authority, 2026). On that basis roughly 67 per cent of the population now holds a health account. The record-to-account ratio has moved above one for the first time. Uttar Pradesh alone accounts for more than 15.3 crore accounts.
The registry layer has also grown beyond the figures above, with about 4.1 lakh facilities registered as at January 2026 (National Health Authority, 2026). The number that matters to a builder is the participant count rather than the citizen count: more than 1,000 private firms are now ABDM-certified, which lets e-pharmacies, hospitals and software vendors exchange records through standardised interfaces. That is a network effect which compounds with every participant and which no single platform can own.
The network is early exactly where it matters most. Adoption of the Unified Health Interface and its network effects remain nascent, and building on
government rails carries a dependency on their pace and on uneven state-level maturity. The rails lower the cost of reach; they do not yet guarantee the demand, and the gap between an issued account and a used one is the quantity nobody publishes.
India’s biggest telemedicine provider is the government, and it charges nothing. That single fact reshapes the market for everyone else.
The most important fact about Indian telemedicine is that its largest provider is the state, and it is free. eSanjeevani, the national teleconsultation platform, passed 43 crore cumulative consultations by November 2025, across every state and union territory: a scale no private
platform comes near. For an ordinary citizen, seeing a doctor online is, increasingly, a free public service.
This is structural, not a footnote, and it cuts two ways. It proves vast latent demand for remote care, and it proves the rails work. It also pins the consumer’s willingness to pay near zero for the exact product private telemedicine is trying to sell. How do you charge for a consultation the state hands out free? The quality picture sharpens the point. Studies put the average eSanjeevani consultation at little more than a minute, and real use of the rails stays shallow beneath the billion-scale account numbers. The rails are built and the demand is proven. What is unproven is that a private operator can carve out a margin in a market where the dominant player gives the product away.
The scale of the free incumbent has since been re-based. The direction is upward. eSanjeevani recorded 50,00,92,730 cumulative teleconsultations on 15 September 2026, having crossed 50 crore, against the 43 crore carried above for November 2025 (MoHFW, 2026). The service covers all 36 states and union territories and is integrated with ABDM. It is supported by roughly 242,000 registered doctors, specialists and health workers. A
public service that has added some seven crore consultations in ten months is not a legacy programme against which private pricing might eventually recover.
The volume arrives through a channel worth naming correctly. Patients without their own devices reach the service through the Ayushman Arogya Mandirs, the facilities renamed from Health and Wellness Centres in 2023. More than 142,000 of them now function as spokes, alongside 19,473 hubs and 901 online out-patient departments (MoHFW, October 2026). The state therefore owns both the consultation and the point of access. That is the part of the public network a private platform cannot replicate at any price.
The strategic reading is unchanged and better evidenced. Basic consultation is occupied, free, and extending into exactly the rural markets where willingness to pay is lowest, so private teleconsultation must compete on specialty depth, clinical quality, convenience and outcomes rather than on
price. The service is simultaneously the strongest evidence that remote demand is real and the clearest constraint on monetising it.
Beneath the apps runs an open, consent-based protocol stack, and it may be where the missing payer comes from.
India’s rails are not one platform but a stack of open protocols, and reading the stack shows where the opportunity lies. The identity layer is ABHA; the records layer is the linked health records; the interoperability layer is the Unified Health Interface, on the Beckn protocol, so any compliant app can find and book consults, diagnostics and pharmacy across providers. And above it all sits the consent layer, the Health Data Management policy and the Consent Manager, governing how data moves.
The consent layer matters because it reaches into the financial system. The Account Aggregator framework, with billions of consented data-sharing accounts, is the money-side twin of the health Consent Manager. Together they make it possible, for the first time, for an insurer to underwrite and pay for outpatient care using verified, consented health and financial data. The stack is more than the rails on which care is delivered. It is the
infrastructure on which a payer could finally be built. The escape route runs straight through this layer.
The stack is better read as five composable blocks than as four layers, and naming them shows where a venture may stop building for itself. ABHA provides the portable identity and health address. The Health Facility Registry provides a national directory of hospitals and clinics, and of labs and pharmacies. The Healthcare Professionals Registry provides a verified directory of practitioners. The Health Information Exchange and Consent Manager moves records on patient authorisation. The Unified Health Interface provides an open protocol for discovery, booking, delivery and payment across any compliant application (National Health Authority, 2026).
The builder thesis follows directly from that list. A venture can authenticate through ABHA, find providers through the two registries and exchange records through the consent manager. A patient on any application can then discover and book any participating provider, which lowers the cost of building both distribution and trust. More than 1,000 private firms are already ABDM-certified, and the interface carries the potential to unbundle the closed platforms, since discovery and booking become an open network rather than a walled garden.
Two cautions belong with the opportunity. Adoption of the Unified Health Interface and its network effects are nascent, so a model that depends on them is taking a timing risk on a government programme rather than on its
own execution. And the consent layer now carries statutory obligations as well as policy ones, since the Digital Personal Data Protection Rules were notified on 13 November 2025, with consent-manager duties falling due from about November 2026. The route to the payer runs through this layer, and so does the compliance cost.
The ceiling is not a vague malaise. It is a specific failure of single-product models: which is why the survivors stopped building them.
The unit-economics ceiling is precise, and naming its mechanics shows exactly why stacking is the only way out:
The conclusion every survivor reaches is the same. No single product is a business. Profit in Indian digital health does not live in any one vertical but in the bundle. A low-margin acquisition product (the consultation) is paired with higher-margin attach products such as diagnostics and pharmacy, and with subscriptions and insurance, until the lifetime value of the whole relationship finally clears the cost of winning it. The next page is about how the survivors actually do it.
The failures are as instructive as the mechanics, and they failed in the ways the mechanics predict. HealthcareMagic could not monetise. Scarce high-quality doctors and low-cost consultations could not support the arithmetic. Medwell Ventures was capital-intensive in labs and centres without sustainable collections, and receivables broke the model. A broad cohort of direct-to-consumer health brands failed at a rate near 80 per cent, having competed on price until margin disappeared (Volge playbook, 2026). In each case acquisition cost exceeded lifetime value at scale rather than at launch, which is why the problem surfaces late.
The survivors share four moves. Only the first is the bundle. The platform model monetises one acquired customer across consultation, pharmacy and diagnostics, so the acquisition cost is amortised across streams, with a path to profit of eighteen to twenty-four months. The business-to-business channel sells corporate group health at acquisition costs of ₹150 to ₹500 per user and higher retention. Niche high-ticket segments such as chronic care, fertility and surgery carry larger fees and more repeat visits.
And the infrastructure play sells to hospitals and clinics rather than to patients, on recurring revenue.
The arithmetic favours two of the seven segments. Provider and clinical software carries the best economics in the sector, on recurring revenue, lower acquisition cost and high switching costs, and it is underbuilt relative to the opportunity. Chronic care and remote monitoring come next, on retention rather than ticket size. India’s competitive position is inversely related to acquisition cost, which is to say it is weakest exactly where the consumer story is loudest.
The route to profit is not a better app. It is a wider bundle, and diagnostics is the keystone.
The companies that reached, or neared, profitability did it by abandoning the pure-play model and stacking complementary revenue until the economics cleared. The pattern is consistent, and the keystone is
diagnostics. A teleconsultation acquires the customer cheaply and earns their trust. A diagnostics order, at 45–50% gross margins and far higher frequency, monetises that trust, and a pharmacy order closes the loop. Subscriptions, pharma advertising and private-label products then stack margin on top.
Tata 1mg is the cleanest proof. It reached EBITDA profitability in its core segments by leaning on a diagnostics business running past ₹600 crore, not on pharmacy or consultation alone. Practo turned profitable the other way, going asset-light, consultation-and-software, dodging inventory and logistics entirely. The lesson holds either way. In a market with no payer and a free public alternative, the road to a margin is to own the whole patient relationship and monetise it across products, not to win one transaction. The question for any operator or investor is not “is the app good?” It is “does the bundle clear the ceiling?”
The move from a single product to a bundle changes the denominator of the ratio rather than the numerator, and that is the whole of the playbook.
One acquisition monetised across consultation, pharmacy and diagnostics carries a blended margin and reaches profit in a stated eighteen to twenty-four months, against a direct-to-consumer consultation that never repays its acquisition cost from a single transaction. The corporate channel is the cheapest version of the same manoeuvre, at ₹150 to ₹500 per user, recurring and sticky, with a sales cycle of three to six months (Volge playbook, 2026).
The bundle has a cost as well as a benefit. Platform models are capital-heavy, and their network effects take years to build. The two leading platforms illustrate both halves of that trade. Tata 1mg reached more than ₹1,900 crore of revenue in FY24 under Tata Digital, while PharmEasy reached ₹5,664 crore in the same year and required a down round to stabilise. Scale and breadth, rather than a single high-margin product, are the route to viability, and the capital needed to assemble them is the barrier.
A third route is now visible beside stacking and asset-light operation. Business-to-business and infrastructure models sold to hospitals, clinics and insurers carry the lowest acquisition cost and the highest switching cost in the sector, and ABDM compliance is creating fresh demand for interoperable provider software. The test for any model remains the same: whether lifetime value clears acquisition cost by a factor of three to five, with payback inside twelve months.
For the sector, that vacuum is the single largest structural risk. A business handling prescription medicines at scale lives under the permanent
possibility that a court ruling or a ministry notification could reshape or restrict it overnight. The uncertainty scares off capital, complicates expansion and shadows every e-pharmacy business case. Set it against the rails and the contrast is stark. India built public infrastructure as good as any for digital health while leaving the largest private segment that runs on it legally unsettled. Resolving the e-pharmacy framework, in either direction, would lift one of the deepest overhangs on the sector.
India’s second-largest digital-health segment has run for seven years with no settled rules whatsoever.
The most striking regulatory fact in Indian digital health is an absence. E-pharmacy, a multi-billion-dollar business serving tens of millions, has operated for nearly seven years with no dedicated, notified regulation. Draft rules surfaced in 2018 and were never finalised, and the Delhi High Court slapped on an interim restriction the same year. The drug regulator fired show-cause notices at some twenty e-pharmacies in 2023. When the court ordered the health ministry in 2024 to frame a policy within four months, the deadline came and went. The proposed devices-and-drugs
bill then stripped out the licensing provisions altogether, handing the government open-ended power to “regulate, restrict or prohibit.”
The dates in the judicial record are routinely conflated, so state them precisely. Draft rules to amend the Drugs and Cosmetics Rules were issued in August 2018 and have never been notified. In November 2023 the Delhi High Court directed the central government to frame a policy within eight weeks, observing that the rules had then been pending for over five years (Delhi High Court, 2023). In the interim, online pharmacies operate under the existing offline drug law and the Information Technology Act, and a pharmacy licence remains necessary to dispense. Marketplaces partner licensed pharmacies and verify prescriptions.
The segment carrying that risk is the largest in the sector by absolute revenue and the most consolidated, dominated by conglomerate-backed platforms. Margins run 15 to 25 per cent on the internal basis, so profitability depends on scale, private label, chronic-refill subscriptions and data, and the business is logistics-heavy and cold-chain dependent (Volge playbook, 2026). The combination of thin margins and contested legal ground is the reason valuations in the segment carry a regulatory discount rather than a growth premium.
The vacuum is unresolved as at the most recent review. No notification had been confirmed as of November 2026, and the segment remains the single largest policy risk in Indian digital health on the crosswalk used internally. Resolution in either direction would reprice the segment, and
continued silence is itself a decision, one that leaves the largest private line in the market permanently provisional.
The new privacy law lands on the most sensitive data of all, and quietly redraws who can do what with it.
Health data is the most sensitive category of personal data there is, and India is finally regulating it, through a horizontal law. The Digital Personal Data Protection Act was passed in 2023, with its rules notified in November 2025. It treats health data as personal data and phases in over eighteen months. A Consent Manager framework arrives from around November 2026, and the substantive obligations and penalties, up to ₹250 crore, from May 2027. For a digital-health business, it lays a binding privacy regime on top of the ABDM consent architecture, which already demands explicit, purpose-bound consent.
The effect is double-edged. On compliance, every platform touching health records has to build consent, audit and breach-response machinery to a new statutory standard before 2027, a real cost, especially for the many sub-scale players. Strategically, though, a strong consent
regime is an enabler: it is exactly the verified-consent plumbing that lets health data be shared safely with an insurer or a bank, which is what the payer escape route depends on. As with the rails themselves, the data regime is a burden today and the foundation of tomorrow’s escape.
The statutory timetable is now specific enough to plan against. The Digital Personal Data Protection Rules were notified on 13 November 2025 as G.S.R. 846(E). Consent-manager duties fall due from about 13 November 2026 and full compliance from about 13 May 2027, with penalties of up to ₹250 crore for serious failures (Ministry of Electronics and Information Technology, 2025). A reported January 2026 proposal to shorten the eighteen-month window to twelve months had not been notified as of October 2026. The later dates remain the planning basis.
The obligations fall unevenly across the seven segments. Provider software and chronic-care monitoring carry the heaviest burden, since both hold longitudinal clinical records. E-diagnostics and teleconsultation sit on explicit consent and prescription record-keeping. Wellness, regulated lightly elsewhere, is brought into scope for the first time by the simple fact of holding health data. Data localisation in India, deletion rights and consent architecture are required of all of them, and the cost falls hardest on the roughly 90 per cent of the base that is sub-scale.
The strategic reading here is the one that applies to the rails generally. A statutory consent regime layered on the ABDM consent manager is the verified-consent plumbing through which an insurer or a bank can be
given health data lawfully, which is the precondition of the payer escape. Compliance is therefore a cost in 2026 and 2027 and an asset thereafter, and the firms that build it early are the ones an insurer can transact with at all.
Even free, even at billion-scale, digital care runs into a quieter limit: whether patients and doctors trust it enough to use it for real.
Below the economics sits a softer but stubborn constraint. Trust and quality are at issue. The billion-scale account numbers on the public rails hide shallow real-world use. Studies find point-of-care utilisation low, and the average free public teleconsultation lasting barely a minute, too short for meaningful clinical engagement. A consultation that is fast, free and superficial proves demand for access, not depth, and it sets a low quality bar that any private platform has to clear to justify charging at all.
The trust gap runs both ways. Patients, first-timers especially, weigh a remote consultation against an in-person doctor they already know; physicians, for their part, often integrate poorly with the platforms and doubt the clinical adequacy of a one-minute call. Building real clinical trust, continuity of care, integration with diagnostics and physical follow-up, demonstrable quality, is itself a cost and a moat. The platforms that win
will be the ones that turn shallow, transactional access into deep, trusted relationships, because only a trusted relationship generates the repeat, multi-product engagement that clears the ceiling. Trust, here, is not a soft virtue. It is the precondition for lifetime value.
The trust constraint has a supply-side counterpart that is easier to quantify than patient sentiment. India has roughly 1.1 million registered doctors for 1.4 billion people, approximately 1.1 doctors per 1,000 population against 2.8 in developed markets, with about 70 per cent of specialists serving the urban third (MoHFW and industry reporting, 2026). Quality is therefore rationed before it is delivered, and a platform competing on clinical depth is competing for the same scarce clinicians who are already oversubscribed in the cities.
Clinical trust is also being rebuilt through tooling rather than through assurance. The share of Indian clinicians using artificial-intelligence tools rose from about 12 per cent in 2024 to 41 per cent in 2025, ahead of the United States and the United Kingdom. Much of that use is documentation rather than clinical decision-making (EY, 2026). Ambient scribing, multilingual triage and decision support reduce the administrative load that makes a one-minute consultation economically rational in the first place. That is a more credible route to depth than exhortation.
Trust is the operative constraint on the escape route as well. An insurer paying for outpatient care underwrites on recorded outcomes, and the segments with the strongest retention, chronic care and remote
monitoring, are precisely those whose moat is outcomes data and sustained engagement. Reimbursement there remains nascent. Depth of relationship is therefore the asset a payer buys, and the platforms without it will have nothing to sell when the payer arrives.
Indian digital health is not one market but seven, each with its own economics, and only some can pay.
The sector splits into segments whose economics diverge sharply, and the divergence explains where value pools. Read across them and the pattern is consistent: the segments that can attach to a higher-margin, higher-frequency product survive; the rest struggle.
| Segment | Economics | Players |
|---|---|---|
| Teleconsultation | High margin, low frequency; free public rival | Practo, Apollo 24/7, MediBuddy |
| E-pharmacy | Thin margins; regulatory vacuum | Tata 1mg, PharmEasy, Netmeds |
| Diagnostics / lab-tech | Margin keystone: 45–50%, repeat demand | Redcliffe, Healthians, Thyrocare |
| Insurtech | Profitable: the payer is built in | Policybazaar, Acko |
| Fitness & wellness | Subscription-led, capital-hungry | Cult.fit |
| Full-stack care | High-value episodes, capital-intensive | Pristyn Care, Apollo |
| Hospital / clinic SaaS | Quiet B2B, recurring revenue | : |
Rank them by economics and the story tells itself: insurtech and diagnostics make money; teleconsultation and e-pharmacy cannot stand alone; and the survivors are the ones that bridge segments. The structure of the market is the whole thesis in miniature.
The taxonomy used internally cuts the sector into seven segments rather than the six lines above, and the two additions are the ones the economics favour. Provider and clinical software, meaning electronic records, practice management and clinic platforms sold to hospitals and doctors, carries recurring revenue, lower acquisition cost and high switching costs. ABDM compliance is now creating fresh demand for interoperable systems. Chronic care and remote monitoring, led by diabetes and cardiac programmes, carries better economics than acute teleconsultation because the relationship recurs. Clinical artificial intelligence is treated as a cross-cutting capability rather than an eighth segment. It appears inside several of the others.
Ranked by economics rather than by revenue, the order is therefore insurtech, provider software, diagnostics and chronic care, with teleconsultation and consumer wellness last. Insurtech is growing at about 29 per cent a year and is regulated by IRDAI. Provider software is underbuilt relative to the opportunity. Wellness, at roughly a tenth of revenue, is brand-led, high in acquisition cost and the segment whose classification as healthcare is most debated (Volge playbook, 2026).
Read the scale of the named leaders against that ranking rather than alongside it. The largest firms in the sector by revenue are e-pharmacy and platform businesses, while the segments with the best unit economics contain the smallest companies. India’s competitive position is inversely related to acquisition cost. The segments where the country is strongest are the quiet, recurring, business-to-business ones, and the segments where it is weakest are the ones that attracted the most capital.
India’s largest private digital-health segment has already changed hands at the top, and why it changed is the lesson.
E-pharmacy is the most-contested segment, and its leadership has already flipped. Tata 1mg overtook PharmEasy, climbing to roughly 31% share by late 2023 while PharmEasy slid from about a third to around 15%, with Netmeds, Apollo and Flipkart Health splitting the rest. The change at the top was not luck. It tracks, almost exactly, the read’s thesis about which models survive.
Tata 1mg won by stacking. The group’s capital and brand backed it, and it built a diagnostics business alongside its pharmacy and rode that higher-margin attach to profitability. PharmEasy lost by over-reaching. It chased growth and acquisitions on cheap capital, piled on debt, and got caught when the funding winter hit. The war was not won on app polish or delivery speed. It was won on balance-sheet discipline and the ability to bolt on a profitable second product. The flip is the clearest market proof of the stack-to-survive playbook, and the clearest warning of what happens to those who chase scale without the economics.
The consolidation that produced the contest predates the leadership change and explains its terms. PharmEasy acquired Medlife in an all-stock transaction in 2021, creating the largest online pharmacy with an estimated
60 to 70 per cent of the segment at that point. Reliance Retail had entered in 2020 by taking 60 per cent of Netmeds for ₹620 crore (Business Standard and Inc42, 2026). The segment arrived at its share war already conglomerate-owned. That is why the decisive variable became the strength of the parent rather than the quality of the application.
The economics beneath the share figures are thinner than the revenue suggests. Gross margins run 15 to 25 per cent on the internal basis, so profitability depends on scale, private label, chronic-refill subscriptions and data, against capital-intensive logistics and a cold-chain obligation (Volge playbook, 2026). Revenue leadership and profit leadership are therefore separable: PharmEasy reported ₹5,664 crore of revenue in
FY24, nearly three times Tata 1mg’s ₹1,968 crore, while losing the strategic contest.
The segment’s legal basis has not improved while its ownership has settled. The governing rules have never been notified, the court direction of November 2023 remains unfulfilled, and no notification had been confirmed as of November 2026. A share war conducted on contested legal ground is a war for a position that a single notification could redefine, which is the reason the segment trades at a regulatory discount irrespective of who leads it.
No company shows the unit-economics ceiling more starkly than the one that ignored it the longest.
PharmEasy is the sector’s cautionary tale. It chased scale and acquisitions on cheap money, and was caught when the economics caught up. Valued at about $5.6 billion at its 2021 peak, its parent ran a rights issue in 2024 at roughly a 90% discount, led by the investor Ranjan Pai, to clear debt taken on mostly to buy the diagnostics chain Thyrocare. By late 2024
some investors were marking the company below $500 million. In FY25 it reported revenue of about ₹5,872 crore, barely growing, and a net loss of roughly ₹1,517 crore, narrowed about 40% only after deep cuts to marketing and staff.
The lesson is precise, and double-edged. PharmEasy’s collapse was a unit-economics failure. It spent through the ceiling to buy growth, and the debt that funded the strategy turned unsustainable the moment capital tightened. Yet its strategic instinct, that diagnostics is the margin keystone, was right. It simply paid far too much and far too late, with borrowed money. The company is restructuring now, cutting acquisition costs and leaning on Thyrocare’s profits. PharmEasy is both the warning and, in its turn toward diagnostics-led discipline, a late convert to the playbook the survivors ran from the start.
The scale of the capital involved is the part that makes the case cautionary rather than merely unfortunate. API Holdings raised about $1.1 billion in total. It acquired Thyrocare for ₹4,546 crore in 2021 for 66.1 per cent of a listed diagnostics chain, bought Aknamed in the same year, and took Retailio and Marg ERP shortly after. It then filed for an initial public offering of up to ₹6,250 crore before withdrawing it in the 2022 and 2023 correction (company filings and Entrackr, 2026). The ₹1,804 crore rescue of 2024 was therefore small beside the sums it was repairing.
The strategic instinct deserves credit, and the sequencing deserves the blame. Diagnostics is the margin keystone, and buying a profitable listed
chain was the fastest route to it. But the purchase was made with borrowed money at the top of the cycle, and the group added hospital supply-chain and distribution software businesses at the same time. Breadth bought at once, rather than built in sequence, is what converted a sound thesis into a debt problem.
The listing question remains the open one. A revived offering has been expected since 2025, conditional on the business turning cash-flow positive, with several observers pointing to late 2026 at the earliest (industry reporting, 2026). Until a pure-play or platform digital-health business lists in India, the base case for an exit in this sector is the conglomerate acquisition, and the public market will continue to apply the same test the private rounds now apply.
Two structural advantages compounded the strategy. The Tata brand and balance sheet lowered both the trust barrier and the cost of capital, letting the company keep investing through the funding winter while rivals pulled
back. The group’s patient money also let it build the diagnostics business competitors had to buy at distress prices. Tata 1mg is the working model for Indian digital health. It is a stacked, diagnostics-anchored bundle on a strong balance sheet, turning low-margin acquisition into a profitable, multi-product relationship. It is also the answer to the ceiling, and a reminder that, here, the economics reward patience and breadth over speed and focus.
If PharmEasy is the warning, Tata 1mg is the template: the company that cleared the ceiling by stacking.
Tata 1mg is the clearest proof the ceiling can be cleared. Backed by Tata Digital, which owns about 63.5%, it reported revenue of roughly ₹2,392 crore in FY25, up 22%. It narrowed its loss to about ₹276 crore and, tellingly, reached EBITDA profitability in its core segments. It got there not on pharmacy or consultation alone. It leaned on a diagnostics arm running past a ₹600 crore run-rate, exactly the higher-margin, higher-frequency attach the playbook calls for.
The trajectory, not the single year, is what distinguishes this company. Revenue rose from more than ₹1,900 crore in FY24 to the figure above in FY25, on about $240 million of capital raised in total. That is a fraction of the roughly $1.1 billion consumed by the segment leader by revenue (company filings and Tracxn, 2026). Capital efficiency, rather than capital access, is the achievement, and it is the metric on which the two platforms separate most cleanly.
The ownership structure is the mechanism rather than the context. Tata Digital acquired its controlling stake in 2021, and the group’s entry was
explicitly an entry into integrated digital health rather than into pharmacy alone. That is why the diagnostics and consultation lines were built alongside the pharmacy rather than bolted on under pressure later. A parent that can fund an eighteen-to-twenty-four-month path to platform profitability without a bridge round is, in this market, a structural advantage that no operating decision can substitute for.
The template is harder to copy than to describe. The bundle requires simultaneous competence in logistics, laboratory operations and clinical supply, each capital-hungry, and the firms holding the best unit economics in the sector, provider software and chronic care, got there by avoiding all three. Tata 1mg is the proof that the ceiling can be cleared at consumer scale, and the clearest illustration of what clearing it at that scale costs.
The contrast with the inventory-led survivors is instructive. Practo carries lower revenue but cleaner economics. Software and consultation marketplaces scale without warehouses, last-mile fleets or working-capital drag. There is no single road through the ceiling. One path stacks higher-margin products onto a heavy operational base; another strips the base away and monetises the connective layer. For an investor the two imply different risk and return, but they share one discipline. Both refused to chase scale at
a loss, and both found a structure where the relationship is worth more than it costs to win. Profitability here is achievable, and by more than one design.
A third route to profit skips the inventory trap entirely: proof there is more than one way to clear the ceiling.
Practo offers the sector’s other profitability model, which is asset-light. Where Tata 1mg cleared the ceiling by stacking inventory-heavy diagnostics and pharmacy, Practo cleared it by carrying no inventory at all. It is a consultation-and-software business that connects patients to doctors and sells software to clinics, without the capital-heavy logistics of delivering medicine. In FY25 it turned profitable, posting operating EBITDA of around ₹15 crore against a loss the year before, and is reportedly in talks to raise pre-IPO capital.
The scale at which this model turns profitable is the point most often missed. Practo reported about ₹240 crore of operating revenue in FY24 on roughly $251 million raised over its life, against platform peers an order of magnitude larger by revenue (company filings and Tracxn, 2026). Profitability was reached at a twenty-fourth of the revenue of the segment leader. That is a statement about the cost base rather than about the
market, and it is the reason the model is replicable by firms that will never raise platform-scale capital.
The software half of the business is the half the economics favour. Provider and clinical software carries recurring revenue, acquisition costs of ₹150 to ₹500 per user and high switching costs, and it is underbuilt relative to the opportunity, with ABDM compliance now generating fresh demand for interoperable systems (Volge playbook, 2026). A consultation marketplace attached to a clinic software business is therefore a chronic-care-style annuity wearing a consumer brand, and the annuity is the part that clears the ceiling.
The limitation sits alongside the advantage. An asset-light operator does not own the diagnostics margin, so its revenue ceiling is lower and its exposure to the platforms that do own it is permanent; and the same firms are now its largest competitors in clinic software. The sector’s most defensible economics and its largest revenue pools sit in different companies, and nothing in the present structure suggests they are about to converge.
The reason is the thesis at its purest. A consultation carries a decent margin but a low ticket and low frequency, and it competes with a free public service. As a standalone business it cannot repay the cost of acquiring its users; as the top of a funnel into diagnostics, pharmacy, insurance or employer contracts, it becomes the cheapest possible start to a profitable relationship. Every serious operator has absorbed the same insight:
teleconsultation is a loss-leader, not a line of business: valuable precisely because it pulls the customer through the door cheaply, so long as a higher-margin product is waiting on the other side.
The segment that defines digital health is also the one that, on its own, cannot pay for itself.
Teleconsultation is the front door of Indian digital health, the largest segment by revenue, around 45%, and the one least able to stand alone. Apollo 24/7, backed by the Apollo hospital group, leads on reach and wires consultation into its pharmacy and diagnostics network. MediBuddy is strong in the corporate, employer-paid niche, a rare pocket where a third party actually pays. Practo anchors the asset-light, software-led approach. Each, in its own way, treats the consultation not as the product but as the cheapest way in to something more profitable.
The corporate pocket deserves more weight than its size suggests, because it is the only place in the segment where a third party already pays. Business-to-business acquisition costs run ₹150 to ₹500 per user against ₹800 to ₹2,000 or more direct to consumer, retention is higher, and the
revenue is recurring and employer-funded, at the cost of a three-to-six-month sales cycle (Volge playbook, 2026). The employer, not the insurer, is the first functioning payer for Indian digital health, and the corporate channel is concentrated in technology and financial services.
The growth of the specialist corporate operator illustrates the point in revenue. MediBuddy moved from ₹645 crore in FY24 to ₹743 crore in FY25 while cutting losses by about 37 per cent, which is the profile of a business whose acquisition cost is paid by somebody else (Entrackr, 2026). Against that, the direct-to-consumer side of the segment competes with a free public service that added some seven crore consultations in the ten months to September 2026.
The strategic conclusion is therefore narrower than the segment’s revenue share implies. Teleconsultation is defensible as a corporate benefit, as a specialty practice in mental health, fertility or dermatology at urban price points of ₹500 to ₹1,500, and as the cheap top of a platform funnel. It is not defensible as a general consumer product, and the segment’s 45 per cent revenue share should be read as the size of a channel rather than the size of a business.
The quiet segment that decides who survives, higher margin, higher frequency, the keystone of every winning bundle.
If teleconsultation is the loss-leader, diagnostics is the profit. With gross margins of 45–50%, well above pharmacy, and higher purchase frequency, online diagnostics is the keystone that turns a stacked business profitable. That is exactly why it sits at the centre of every survivor’s strategy. The segment is competitive and consolidating. Redcliffe Labs reported about ₹419 crore in FY25, Healthians around ₹263 crore and nearing breakeven, and Orange Health smaller and loss-making. The established, profitable incumbent Thyrocare, now PharmEasy-controlled, posted about ₹687 crore and a healthy profit.
| Diagnostics player | FY25 revenue | Profitability |
|---|---|---|
| Thyrocare (PharmEasy-controlled) | ~₹687cr | Profitable |
| Redcliffe Labs | ~₹419cr | Narrowing losses |
| Healthians | ~₹263cr | Near breakeven |
What makes diagnostics decisive is that everyone wants to own it. Tata 1mg’s profitability rests on it. PharmEasy’s entire debt-fuelled gamble was an attempt to buy it, and the asset-light players partner for it. The reason is structural. Diagnostics pairs a defensible margin with repeat demand (tests get ordered regularly, consultations do not) and a natural attach to the consultation that comes before it. In a market with no payer and a free public consultation, diagnostics is where the unit economics finally turn positive, which makes it the single most contested layer in Indian digital health.
The segment’s moat is operational rather than commercial, which is why it resists the acquisition-cost problem that defeats consultation. Home sample collection is logistically complex and capital-intensive, and the defensible assets are turnaround time, trained phlebotomy at the door, and accreditation under NABL or ISO 15189 (Volge playbook, 2026). Those are assets that take years to assemble and cannot be bought with marketing spend, which is precisely the opposite of the position in teleconsultation.
The competitive field is wider than the digital-native names suggest. Diagnostics and e-pharmacy together account for roughly 30 per cent of
sector revenue. The online aggregators compete not only with one another but with the established offline pathology chains, Dr Lal PathLabs and Metropolis among them. Those chains are moving online with existing laboratory networks and brand trust already built. Healthians reached EBITDA breakeven on about ₹243 crore of revenue in FY24, which indicates the scale at which the segment’s economics begin to work (Entrackr, 2026).
Every structural route out of the unit-economics ceiling passes through this segment. The platform bundle uses diagnostics to monetise the consultation, the asset-light operators partner for it, and the one debt-funded attempt to buy it outright reshaped the e-pharmacy league table. A segment that is simultaneously the profit lever for the consumer platforms and a going concern in its own right will continue to be the most contested layer in Indian digital health.
That is why insurtech is more than another segment; it is the wedge toward the market’s missing payer. Commercial health insurance is now the
largest non-life line in India, growing fast, and pushed further by the 2025 removal of GST on individual premiums. As more Indians gain private outpatient cover, and as the Account Aggregator consent rails let insurers underwrite on verified health data, an actual payer for digital health starts to take shape. The insurtech players already stand at the exact spot where the market’s central problem is solved: where someone other than the patient finally pays. The escape route runs through this segment.
The most profitable corner of digital health is also the one that points straight at the market’s missing piece.
Insurtech is the exception that proves the rule. While telemedicine and e-pharmacy strain against the ceiling, digital insurance is the sector’s standout. PB Fintech, parent of Policybazaar, reported FY25 revenue of about ₹4,977 crore and net profit of around ₹353 crore, and Acko reached roughly ₹2,837 crore. The difference is the model. Insurance has a payer built in. The insurer collects a premium and pays for care, so the economics rest on underwriting and distribution, not on squeezing a margin out of a one-off consultation.
The segment is the fastest-growing of the seven, at roughly 29 per cent a year, and the specific entry point matters more than the growth rate. Group health lowers acquisition cost and brings recurring, employer-funded revenue. Claims technology and benefits administration are the other two wedges. The segment is also regulated by IRDAI, which makes it the most legally settled part of the sector as well as the most profitable (Volge playbook, 2026). Consolidation has begun, the defining transaction being the merger of RenewBuy into InsuranceDekho at about ₹7,400 crore in May 2025.
The premium data behind the segment’s claim to be the escape route is now unambiguous. Health insurance became the largest line in India’s non-life market in FY26 at 40.8 per cent of gross premium, from 38.6 per cent in FY25. Segment premium was up 15.4 per cent to about ₹1.4 lakh crore and retail health up 19.9 per cent, against industry growth of 9.3 per cent (IRDAI and CareEdge Ratings, 2026). The market is estimated near $16 billion in 2025, reaching about $48.5 billion by 2035.
The composition of that growth decides whether the escape materialises. The relevant white spaces are out-patient cover, mental-health cover,
senior inclusion, rural penetration and prevention-led digital engagement, and the regulator capped annual premium increases for senior citizens at 10 per cent in January 2025. Premium growth in hospitalisation cover alone would leave the digital-health ceiling exactly where it is.
Full-stack care, integrated providers that own the journey from consultation to surgery, like Pristyn Care, runs the opposite bet. The wager is that owning the whole, high-value episode (an elective surgery, not a consultation) is where the economics live. It carries higher revenue per patient but also heavy operational complexity and capital intensity. Pristyn cut staff and exited cities in 2024 as it hit the same ceiling from a different angle. Together, fitness and full-stack make the same point. No clever model escapes the underlying maths. Recurring revenue and high-value episodes
both help, but neither substitutes for the discipline of matching what a customer is worth to what it costs to serve them.
Two neighbouring models test different answers to the ceiling, the subscription, and owning the whole patient journey.
Two more segments map the range of strategies and their costs. Fitness and wellness, led by Cult.fit, runs the subscription bet that should, in theory, smooth the economics through recurring revenue. In practice it stays capital-hungry, with FY25 revenue of about ₹1,216 crore (up 31%) but a loss of roughly ₹481 crore, as the cost of winning and keeping members and building physical centres bites hard. Subscriptions help the lifetime-value side of the equation, but acquisition and fulfilment costs in a price-sensitive market keep profit out of reach.
The segment contains a profitable counter-example that qualifies the loss-making case. HealthKart, a direct-to-consumer nutrition and wellness business, reported ₹1,021 crore of revenue in FY24 with a profit after tax of ₹38 crore. HealthifyMe, at ₹80 crore to ₹100 crore of revenue, is reported at or near profitability (Entrackr and company filings, 2026). Product-led
wellness, where the transaction is a repeat purchase rather than a subscription to a physical network, clears the ceiling on gross margin and brand. Subscription plus bricks (the model above) does not.
Consumer wellness is roughly a tenth of sector revenue and the segment whose classification as healthcare is most contested, which matters for how it should be valued. Acquisition cost is high, churn is a constant risk, and the moat is brand, community and in some cases hardware, with Ultrahuman differentiated by its wearable (Volge playbook, 2026). It is treated internally as an adjacent consumer category rather than as clinical care, and the premium placed on it should be a consumer-brand premium rather than a health-technology one.
On the full-stack side, the valuation evidence confirms the operational retrenchment described here. Pristyn Care stood at about $1.17 billion in November 2025, down some 17 per cent from its $1.4 billion peak, on ₹601 crore of FY24 revenue and about $187 million raised. High-value episodes
do raise revenue per patient, and they raise fixed cost and clinical liability in the same movement.
After the reset, the money flows to consolidation and the proven, and the deals show exactly where value is now seen.
The capital reordering of 2024–2026 tells the read’s story in transactions. The defining deal was strategic, not venture. In 2024, Advent put about ₹2,475 crore into roughly 12% of Apollo’s health-tech and pharmacy business (HealthCo), valuing it near ₹22,481 crore. Advent then merged it with the Keimed distribution business, assembling an integrated, profitable, IPO-bound platform that is the stacked model made concrete. Alongside it, PharmEasy raised emergency capital at a 90% discount, and the sector logged at least eight mergers and acquisitions by late 2025 as consolidation replaced growth-at-all-costs.
The capital mirrors the market exactly. Money now flows to the firms that have solved the unit economics: the stacked, the profitable and the strategically backed. It flows away from the single-product loss-makers. Strategic and institutional capital (Tata, Apollo, Advent) is consolidating the sector into a handful of integrated platforms. Venture capital, reset to about $700 million a year, is selective and tilting toward AI and specialist verticals
rather than the old consumer plays. For an investor the message is consistent. The opportunity is investable, but the diligence question has shifted from “how fast is it growing?” to “does the model clear the ceiling, and is there a payer in sight?”
The acquirer list is short, domestic and strategic, and it is the defining feature of the deal record. Tata Digital took about 65 per cent of 1mg in 2021. Reliance Retail took 60 per cent of Netmeds for ₹620 crore, and made a strategic investment in the oncology platform Karkinos in 2024. PharmEasy assembled Medlife, Thyrocare, Aknamed, Retailio and Marg ERP, while InsuranceDekho merged with RenewBuy at about ₹7,400 crore in May 2025. The Manipal family office stabilised PharmEasy with ₹1,804 crore in 2024 (Business Standard, Inc42 and Entrackr, 2026). Conglomerates and family offices, not venture funds, now set the price.
The venture side has repriced rather than withdrawn. Funding reached about $1.13 billion across 112 deals in 2024, and about $496 million across
38 rounds in the first quarter of 2025. Roughly 30 per cent of health-technology venture capital is now directed to medtech and diagnostics rather than to teleconsultation. Only four rounds above $100 million were recorded nationally in the first half of 2026, against eleven a year earlier (Tracxn, 2026). The investor base has also broadened, with development-finance and impact capital funding access-led models that commercial funds will not.
The exit question remains unresolved, and it governs the capital cycle above it. Strategic acquisition or a private-equity secondary is the realistic exit; the public route awaits the first listing, most plausibly a platform or an insurtech-adjacent business that reaches profitability first. Until then, the sector’s terminal value is set by five or six domestic buyers.
The more distinctive play is frugal AI aimed straight at the doctor gap. ASHABot, built with Microsoft Research, hands a million community health workers a multilingual AI assistant over WhatsApp. eSanjeevani itself added AI-driven differential diagnosis across hundreds of symptoms in 2025. The logic is hard to fault. AI scales clinical expertise without the doctors India lacks, runs on rails already built, and plays to a software strength rather than a hardware or capital weakness. It even sidesteps the
unit-economics ceiling in part, because much of it sells to institutions and governments, payers, in other words, rather than to individual patients. Of every route out of the ceiling, clinical and frugal AI is the one where India can lead rather than follow.
The one layer where Indian digital health might build genuinely global products, and relieve its deepest shortage at the same time.
The most promising frontier in Indian digital health is artificial intelligence, because it attacks the country’s real clinical bottleneck, too few doctors, not too little demand, with the input India has in abundance. Qure.ai, a radiology-AI firm that raised $65 million in 2024, runs algorithms that read scans and screen for disease across more than a hundred countries. Those algorithms were used for tuberculosis screening at the 2025 Maha Kumbh, and Niramai builds radiation-free breast-cancer screening. These are global products built from an Indian base, in the mould of the country’s IT industry.
Adoption has moved faster than the exporter story suggests, and the adopters are clinicians rather than institutions. The share of Indian doctors using artificial-intelligence tools rose from about 12 per cent in 2024 to 41 per cent in 2025, ahead of the United States and the United Kingdom. Much of that use is documentation rather than clinical decision-making (EY, 2026). The domestic build is following the same path. Eka Care has launched an India-first ambient scribe on purpose-trained language models, converting multilingual consultations into structured notes and prescriptions. Sarvam AI deploys voice-enabled multilingual triage agents over WhatsApp and low-bandwidth interfaces.
The frugal claim can be quantified. Small, domain-specific models tuned for Indic languages and voice-first use are reported to cut inference costs by 60 to 97 per cent against general-purpose alternatives (industry reporting, 2026). That is the difference between a feature that can be given to a rural health worker and one that cannot. Public-health deployment is already measurable in outcomes rather than in usage. Government screening programmes in tuberculosis and diabetic retinopathy have been associated with a 27 per cent decline in adverse tuberculosis outcomes.
Two limits bound the claim. These systems are positioned as decision support rather than autonomous diagnosis. Where the software performs a medical function in its own right it is regulated by CDSCO as a Class C
device, carrying a clinical validation and approval burden that consumer software does not. Accuracy, governance, liability and the DPDP obligations all apply. Read correctly, the layer is an accelerant across all seven segments, strongest where it relieves the labour constraint rather than where it replaces the clinician.
The export claim now rests on a clearance record rather than on a funding round. Qure.ai's chest X-ray detection product won a six-indication 510(k) class II clearance on 26 February 2026. That took the company to 26 cleared indications across nine products for X-ray and computed tomography, against more than 65 certified indications in Europe (Imaging Technology News, 2026). It is a regulatory asset. The same product is the only chest X-ray detection device cleared with a predetermined change control plan, which allows the model to be revised without a fresh submission each time. The asset compounds abroad. Every added indication widens the hospital base without adding an Indian consultation to the count.
The domestic rule book caught up in the same year, and it raises the bar for everyone building here. The Central Drugs Standard Control Organisation issued its final guidance document on medical device software on 21 July 2026. The document runs to 62 pages and sits under the Medical Devices Rules of 2017 (Nishith Desai Associates, 2026). It is not a new statute. Every developer is now asked to state the specific medical purpose of its software. That statement decides whether the product is read as
decision support or as a definitive diagnosis, and risk class follows from it rather than from marketing language. The ambient scribe and the voice triage agent will therefore be tested against the same instrument as the radiology algorithm.
Below the economics lies the reason the rails exist at all: a country with too few doctors, in the wrong places.
The demand is real and structural. India does not have enough doctors, and the ones it has cluster in the wrong places. On the most defensible measure, India has roughly one allopathic doctor per 2,700 people (the government cites a far rosier ratio by counting traditional-medicine practitioners and assuming high activity rates). The maldistribution is severe. About 80% of doctors serve cities holding less than a third of the population, and rural community health centres run a specialist shortfall of roughly 80%. This is the gap digital health exists to bridge, and the reason the state built the rails in the first place.
The shortage explains both the opportunity and the constraint. The opportunity is enormous: remote consultation and AI triage can stretch scarce expertise to hundreds of millions who cannot reach a specialist, which is why eSanjeevani’s 43 crore consultations matter as proof of need. The constraint is that the same shortage suppresses willingness to pay (a patient with no local doctor will take a free remote one) and starves private platforms of physicians to staff them. Digital health is, at bottom, India’s
answer to a doctor shortage it cannot fix any other way, any time soon. The purpose is clear. The problem is paying for it.
The absolute numbers behind the ratio set the ceiling on everything the sector can deliver. India holds roughly 1.1 million registered doctors for a population of 1.4 billion, approximately 1.1 doctors per 1,000 against 2.8 in developed markets, alongside a hospital-bed shortage estimated near 1.5 million (MoHFW and industry reporting, 2026). No digital model creates a clinician, so every platform in the market is competing for slices of the same constrained supply, and the free public service has first call on a large part of it.
The public response to that shortage is now measurable at the level of infrastructure rather than of consultations. More than 142,000 Ayushman Arogya Mandirs operate as telemedicine spokes, against 19,473 hubs and 901 online out-patient departments, served by roughly 242,000 registered providers, and the cumulative consultation count passed 50 crore on 15 September 2026 (MoHFW, 2026). The hub-and-spoke design is the state’s answer to maldistribution: the specialist stays in the city and the consultation travels.
The market splits along the same line, and the split determines strategy. Urban tier-one markets generate over 70 per cent of platform revenue, at ₹500 to ₹1,500 a consultation, and are saturated and commoditised. Rural and tier-two and tier-three markets hold the larger supply gap, with limited willingness to pay and the government scheme as the primary channel.
That channel reimburses at ₹50 to ₹200 per consultation on cycles of 90 days or more. The hybrid is therefore the only viable shape, with urban margin subsidising public-channel reach.
The mechanism is specific. An insurer that pays for a member’s digital consultation, diagnostics and pharmacy turns those products from patient-funded, price-sensitive, one-off purchases into payer-funded, managed, recurring care: absorbing the acquisition cost and rewarding the engagement that lowers claims. The insurtech players are already standing at that junction. The escape route is not speculative; it is visible in the data and the deals. What is uncertain is timing, how fast outpatient insurance penetrates, how quickly the consent rails get used to fund care, and which
platforms position themselves to be paid by the payer when it arrives. Whoever wires digital-health delivery to the emerging payer captures the market.
What this market needs is not a better app or a bigger market. It is the arrival of a payer.
If the missing payer is the disease, the cure is the emergence of one, and the likeliest candidate is private health insurance, riding the rails the state has already built. The pieces are assembling. Commercial health insurance is now the largest non-life line in India and growing fast, and the 2025 removal of GST on individual premiums lowers the barrier to cover. The Account Aggregator consent framework, with billions of enabled accounts, gives insurers the verified data to underwrite and pay for outpatient care for the first time. As more Indians get private cover that includes outpatient benefits, someone other than the patient finally pays for the consultation and the medicine, and the ceiling lifts.
The premium data now supports the claim with specificity rather than direction. Health insurance became the largest line in India’s non-life market
in FY26, at 40.8 per cent of gross premium against 38.6 per cent in FY25. Premium was up 15.4 per cent to about ₹1.4 lakh crore and retail health up 19.9 per cent, against industry growth of 9.3 per cent (IRDAI and CareEdge Ratings, 2026). The removal of the 18 per cent GST on individual life and health premiums took effect on 22 September 2025, group health remaining taxed at that rate. The market is estimated near $16 billion in 2025 against about $48.5 billion by 2035.
The public payer has also begun to move, which the argument above does not yet credit. PM-JAY has started reimbursing teleconsultation in selected states, and the scheme has been extended to citizens aged 70 and above, on a base of 48.5 crore cards issued by 21 September 2026 (National Health Authority, 2026). Public reimbursement is slow, at cycles of 90 days or more, and low, at ₹50 to ₹200 a consultation. It therefore buys volume rather than margin. But it establishes the principle that the state will pay for a consultation delivered remotely.
The sequence that matters is therefore composition before scale. Out-patient cover, mental-health cover, senior inclusion, rural penetration and
prevention-led digital engagement are the specific white spaces, and the corporate channel, already employer-funded, is the one operating today. The platform positioned to be paid by the payer is the one already paid by an employer.
The path is navigable, but the obstacles are specific, and several could keep the market loss-making for years yet.
Five constraints gate Indian digital health, and each of them binds on its own timetable:
Three risks could keep the market subscale. The payer may not arrive fast enough, outpatient insurance could penetrate slowly, leaving the economics broken for years. The e-pharmacy framework could turn restrictive, hitting the largest private segment overnight. And consolidation could leave a few profitable integrated platforms sitting atop a long tail of failures, healthy for the survivors, a contraction for the sector. None of these reverses the structural demand. Each shapes how long the market stays loss-making, and who is left standing when it turns.
Two constraints belong on this list that are not yet on it, and both are structural rather than cyclical. The first is clinical supply. Roughly 1.1 million registered doctors serve 1.4 billion people, and medical practice is regulated by state medical councils. Cross-state teleconsultation therefore requires multiple registrations, and the licensure friction is permanent rather than transitional. The second is the data regime. Full compliance with the DPDP Rules falls due from about 13 May 2027, with penalties up to ₹250 crore, and the cost falls hardest on the roughly 90 per cent of the base that is sub-scale (MeitY, 2025).
Cash conversion is the constraint that kills firms before any of the above resolves. Reimbursement cycles of 60 to 90 days are normal in corporate and government channels. Public reimbursement runs at ₹50 to ₹200 a consultation on cycles of 90 days or more. That strains working capital
in exactly the channels that offer the lowest acquisition cost. Rural last-mile logistics and cold chain compound the same problem on the fulfilment side.
The expected shape of the contraction is now quantified. An estimated 20 to 30 per cent of the roughly 11,000-firm base is likely to fail or be absorbed within two years. The top five firms already hold about 60 per cent of revenue in teleconsultation and e-pharmacy (Tracxn and industry trackers, 2026). The risk to the sector is therefore not collapse but concentration. It is a market that functions for five or six platforms and for almost nobody else.
The binding question is the payer. The rails are built and the demand is proven; whether the market becomes large and profitable, rather than
large and loss-making, comes down to how fast a payer for outpatient digital health emerges. The smart position, for operator and investor alike, is to build the bundle that survives without a payer, and to be ready to be paid by one when it comes.
What Indian digital health should look like by 2028, if the next three years run true to form.
Over the next two to three years, the sector will consolidate around the firms that have solved the unit economics, and its centre of gravity will shift toward the payer. Four developments look most likely:
The quantitative frame for the period is a market of roughly $15 billion to $18 billion in 2025, compounding at 20 to 25 per cent. The $100 billion-plus figure for 2033 is best read as direction rather than forecast (Custom Market Insights and Mordor Intelligence, 2026). The narrower telehealth sub-market, at about $3.9 billion in 2025 and some $9.8 billion by 2030, is the more useful series for anyone underwriting a consultation-led business. The gap between the two defines how much of the headline belongs to enterprise software rather than to consumer care.
Three developments can be dated rather than estimated. Consent-manager duties under the DPDP Rules fall due from about November 2026 and full compliance from about May 2027, which will clear a tranche of sub-scale operators out of the records business. The GST exemption on individual health premiums, effective 22 September 2025, works through renewal cycles over the same period. And the device-adjacent clinical-AI layer continues to sell to institutions and governments, which is the only part of the sector that already has a payer.
The value migration is the forecast worth holding. Value is expected to move from acute teleconsultation towards chronic care, provider software and infrastructure, where retention and margin are stronger. The public rails are expected to become the default substrate, so that ABDM-native and government-channel models gain ground against direct-to-consumer plays. The binding question remains execution on unit economics rather than the arrival of the market.
The whole argument, in one place, with the evidence behind it.
India has built public rails for digital health that rank with any, 90 crore identities, a billion records, 43 crore free consultations, on top of vast, structural demand driven by a doctor shortage and a heavy disease
burden. And yet the private market running on those rails is almost entirely loss-making, because of a unit-economics ceiling no pure-play model clears: every leader still spends more to win a customer than that customer is worth. The deepest reason is the missing payer, India’s public insurance covers the hospital but not the clinic, so no one but the patient pays for the outpatient care digital health sells.
The survivors answered the ceiling by stacking, anchoring a profitable bundle on diagnostics, as Tata 1mg did, or stripping out inventory entirely, as Practo did, while the over-extended, PharmEasy chief among them, became cautionary tales. The structural fix is a payer, and the likeliest one is private health insurance, riding the consent rails the state has already laid. And the one frontier where India can lead rather than follow is software, clinical and frugal AI, which scales scarce expertise and sells, in part, to institutions that actually pay.
For the operator and the investor, the read is to build for the ceiling and the payer at once: a bundle that survives the unit economics today, positioned to be funded by the payer that arrives tomorrow.
The figures on which the argument rests have been re-based since this read was first set, and all of them move in the same direction. The public
identity layer stands at about 93.95 crore ABHA health accounts and some 105 crore linked records (National Health Authority, July 2026), roughly two thirds of the population. The free national teleconsultation service passed 50 crore cumulative consultations on 15 September 2026. Delivery runs through more than 142,000 Ayushman Arogya Mandirs, the facilities renamed from Health and Wellness Centres in 2023 (MoHFW, 2026). The rails are larger, and so is the free alternative.
The payer side has moved for the first time in the series. Health insurance became the largest line in India’s non-life market in FY26, at 40.8 per cent of gross premium against 38.6 per cent in FY25, with retail health up 19.9 per cent. That followed the removal of GST on individual health and life premiums from 22 September 2025 (IRDAI, CareEdge Ratings and the 56th GST Council, 2026). PM-JAY, at 48.5 crore cards and more than 38,000 empanelled hospitals as at 21 September 2026, has begun reimbursing teleconsultation in selected states while still excluding out-patient care generally.
The conclusion is therefore unchanged in structure and sharper in timing. The ceiling is intact, the rails are stronger, and the payer is closer than at any point since the sector began. What remains unresolved is whether out-patient cover deepens fast enough to fund digital care before consolidation leaves five or six platforms and little else to fund.
Nine conclusions for the people who must act on this market.
The engineering work the sector asks for, and the form it takes on an engagement.
India's digital health market runs on public rails and private unit economics, so the engineering it needs is integration on one side and instrumentation on the other. The work below is what providers, platforms and insurers in this market commission. Each is delivered by senior engineers working inside the client's own team, with the Global Delivery Centres running what has been built once it is in production.
A platform in this market needs its unit economics instrumented before it needs more features. Contribution per user, measured per transaction rather than per cohort, is the number that decides whether integration with the public rails is an asset or an expense. Few platforms can produce it on demand. Volge treats the instrumentation as the first deliverable, because every later argument about attach rates and retention is settled with that number or not settled at all.
Consent is a statutory obligation in India now, and it is not a user-interface problem. The data protection regime requires a record of what was consented to and when, retrievable on request (Government of India, 2023).
The health account and record-linking interfaces of the national mission impose their own conformance tests before go-live (National Health Authority, 2021). Both move. A platform that passes once and stops testing will fail quietly, usually at the point a payer wants to connect to it.
This work is sequenced, not parallelised. Identity and consent are settled first, because claims and records integration is worth nothing without them, and the instrumentation goes in alongside rather than afterwards. The opening quarter should close with one live integration and a cost per transaction that the finance team recognises as its own. Volge staffs it with a small embedded team under one architect, who stays through operations rather than handing over at the end of the build.
Measure the platform, not the programme. Contribution per transaction and the share of claims adjudicated without manual intervention tell a board more than a release count ever will, and both are available weekly. The failures here are commercial as often as technical. Platforms build on the public rails with no payer at the other end, and they treat diagnostics or pharmacy attach as a growth number when it is in fact the only margin in the business.
The bodies cited in this read for market size, adoption, funding and regulation, with the year the text attributes to each.
Volge is an engineering firm providing enterprise technology transformation services to clients across the Middle East, India, APAC, Europe, and North America.
Delivery stands on two pillars: Forward Deployed Engineering, with senior specialists embedded in the client’s own team, and Intelligent Command Centre Operations, run from our Global Delivery Centres, which keeps what they build running. Senior engineers stay with an engagement from the first diagnosis through to production.
Our services span Strategy, Data, Platforms, AI and Automation, Cyber Trust, Technology Operations, and Applied Functional Engineering. Engagements begin with a diagnosis. The firm is built on working autonomy: engineers decide, innovate, co-create, and own their work. Motivated engineers build the systems that sustain our clients’ growth.
This edition may be shared with organisations evaluating a Volge engagement. It may not be altered or republished without Volge’s permission, and figures carry their stated basis and date. Volge, Intelligent Command Centre, and Intelligent Command Centre Operations are marks of Volge; other names are the trademarks of their respective owners.